as soon as is submitted to ZB.
The autophagy machinery interacts with EBV capsids during viral envelope release.
Proc. Natl. Acad. Sci. U.S.A. 120:e2211281120 (2023)
Autophagy serves as a defense mechanism against intracellular pathogens, but several microorganisms exploit it for their own benefit. Accordingly, certain herpesviruses include autophagic membranes into their infectious virus particles. In this study, we analyzed the composition of purified virions of the Epstein-Barr virus (EBV), a common oncogenic γ-herpesvirus. In these, we found several components of the autophagy machinery, including membrane-associated LC3B-II, and numerous viral proteins, such as the capsid assembly proteins BVRF2 and BdRF1. Additionally, we showed that BVRF2 and BdRF1 interact with LC3B-II via their common protein domain. Using an EBV mutant, we identified BVRF2 as essential to assemble mature capsids and produce infectious EBV. However, BdRF1 was sufficient for the release of noninfectious viral envelopes as long as autophagy was not compromised. These data suggest that BVRF2 and BdRF1 are not only important for capsid assembly but together with the LC3B conjugation complex of ATG5-ATG12-ATG15L1 are also critical for EBV envelope release.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Ebv ; Autophagy ; Viral Capsid Assembly ; Viral Envelope ; Xenophagy; Epstein-barr-virus; Extracellular Vesicles; Proteins; Replication; Infection; Blocks; Fusion; Roles; Motif; Flux
ISSN (print) / ISBN
0027-8424
e-ISSN
1091-6490
Quellenangaben
Volume: 120,
Issue: 34,
Article Number: e2211281120
Publisher
National Academy of Sciences
Publishing Place
2101 Constitution Ave Nw, Washington, Dc 20418 Usa
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Research Unit Gene Vector (AGV)
Grants
Novartis
Cancer Research Center Zurich
Swiss NSF
Vontobel Foundation
Roche
Swiss MS Society
Swiss Vaccine Research Institute
Sobek Foundation
HMZ ImmunoTargET of the University of Zurich
Cancer Research Switzerland
Forschungskredit of the University of Zurich
Cancer Research Center Zurich
Swiss NSF
Vontobel Foundation
Roche
Swiss MS Society
Swiss Vaccine Research Institute
Sobek Foundation
HMZ ImmunoTargET of the University of Zurich
Cancer Research Switzerland
Forschungskredit of the University of Zurich